Creative Biolabs is using exosome display technology to promote the development of membrane protein therapies by generating and isolating antibodies against various pharmacological targets.

Exosome Display of Different Proteins

There are two ways that proteins can enter exosomes. The extracellular domains of receptors and soluble proteins are subject to the first transfer way. Generally, the C1C2 domain of lactadherin is used to address the proteins to the exosome surface. All transmembrane membrane proteins fall under the second mode. Due to the difficulties of obtaining purified soluble transmembrane proteins in their native conformation, exosomes have been used as a display platform to present and overexpress these proteins on exosomal surfaces. Exosome display of proteins offers many advantages, including:

• Provide an environment that is conducive to the appropriate conformation, activity, and dispersion of membranes.
• Offer many possibilities to tailor exosomes with desirable functions.
• Represent a unique and cost-effective antigen presentation platform to enrich membrane proteins for antibody development.

ExoMAb Approach for Antibody Development against GPCRs

The application of Exosome Display to the generation of antibodies is called the ExoMAb approach. This approach applies to antibody induction and screening in situations where the antigen is either difficult to produce or poorly immunogenic. Besides, the induction of antibody responses upon immunization with antigen bound to exosomes may be achieved while maintaining the scale of immunogen preparation to a minimum due to the potent adjuvant activity of exosomes. Furthermore, antigen purification—which is carried out in conjunction with the purification of exosomes under non-denaturing conditions—is time-consuming and expensive when using ExoMAb technology. This process involves 2 key steps:

• Recombinant exosomes bearing target antigens are generated, purified, and characterized, followed by immunization of animals (e.g., mice) to induce antibody responses.
• Labeled recombinant exosomes are used to screen and/or sort antibody repertoires to identify and isolate antibody-producing cells. Antibody repertories can be primary cells, hybridoma from immunized mice, or libraries of recombinant antibodies.

Fig. 1 The chemical and biological modification on exosome surfaces.¹

Features

• Custom-specific project designs that allow antibody development against different antigens, especially GPCRs
• Professional scientists and employees collaborate closely with clients to deliver gratifying customer care support
• Streamlined services ranging from project design and consultancy to product manufacturing and data analysis
• Guaranteed superior quality, reliable repeatability, and prompt delivery
• Suitable for various downstream applications and research objectives

Scientists in Creative Biolabs have been working on exosome research for many years, especially specializing in exosome display for antibody production. We are confident in offering the best exosome antibody development services based on exosome display techniques. Please contact us and start the conversation.

FAQs

Reference

1. Zhang, Ying, et al. "Recent advances in exosome-mediated nucleic acid delivery for cancer therapy." Journal of nanobiotechnology 20.1 (2022): 279. Under Open Access license CC BY 4.0, without modification.

• Exosome Display-based Protein Array Screen
• Exosome Display-based Targeted Delivery